Carlo Rizzuto

Interim CEO

Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need.

Stablix

biotechnology

carlo.rizzuto@stablix.com


Kevin Sprott
SVP of Drug Discovery and Co-Founder
Stablix
Biotechnology
United States
Scott Kanner
Head of Platform Development and Co-Founder
Stablix
Biotechnology